The HVTN 503/Phambili study , which assessed the efficacy of the Merck Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine in South Africa , was stopped when futility criteria in the Step study ( assessing the same vaccine in the Americas , Caribbean , and Australia ) were met .